Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

The BLA submission is based on the primary analysis data of the IGNYTE trial, which evaluated RP1 in combination with nivolumab in patients ... of Replimune's data package, setting the stage ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

The BLA submission is based on the primary analysis data of the IGNYTE trial, which evaluated RP1 in combination with nivolumab in patients with advanced ... over the sufficiency of Replimune's data ...

The immunotherapy used in the trial was nivolumab (Opdivo), a drug delivered intravenously that works by disabling a protein on the surface of cancer cells called PD-1. This helps the patient's ...

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to ...